Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors

• Status: Not yet recruiting
• Trial end date: 2025-10-22
• Target enrollment: 0
• Participant gender: All

Summary

This trial is a phase I/II study, which is designed to evaluate the safety, tolerance, pharmacokinetic characteristics, receptor occupancy (RO), immunogenicity and effectiveness of LBL-019 monotherapy or combined with anti-PD-1 antibody in patients with advanced malignant tumors.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nanjing Leads Biolabs Co.,Ltd
• Treatments: Antibodies; Immunoglobulins

Criteria

Inclusion Criteria:

1.Agree to comply with the trial treatment plan and visit plan, voluntarily agree to sign the informed consent form;

2.18-75 years old (including boundary value), no gender limit;

3. previous standard treatment failed, no standard treatment or standard treatment is not applicable at this stage;

4.The expected survival time is at least 12 weeks;

Exclusion Criteria:

1. Have received chemotherapy, radiotherapy, biological therapy, endocrine therapy, immunotherapy and other anti-tumor treatments within 4 weeks before using the study drug for the first time；

2. Received any other investigational drug or treatment that is not on the market within 4 weeks prior to the initial use of the investigational drug;

3. Women who are pregnant or breastfeeding;

4. The investigator believes that the subject has other conditions that may affect compliance or are not suitable for participating in the study